Antonio Medina de Almeida
AuthID: R-000-T91
61
TÃTULO: The Bone Marrow-Mediated Protection of Myeloproliferative Neoplastic Cells to Vorinostat and Ruxolitinib Relies on the Activation of JNK and PI3K Signalling Pathways Full Text
AUTORES: Cardoso, BA; Belo, H; Barata, JT; Almeida, AM;
PUBLICAÇÃO: 2015, FONTE: PLOS ONE, VOLUME: 10, NÚMERO: 12
AUTORES: Cardoso, BA; Belo, H; Barata, JT; Almeida, AM;
PUBLICAÇÃO: 2015, FONTE: PLOS ONE, VOLUME: 10, NÚMERO: 12
62
TÃTULO: CLINICAL FACTORS PREDISPOSING TO ACHIEVEMENT OF RBC TRANSFUSION INDEPENDENCEIN LENALIDOMIDE-TREATED PATIENTS WITH LOW/INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES) WITHOUT DEL(5q) IN MDS-005 STUDY Full Text
AUTORES: Santini, V; Shiansong S S Li; Swern, AS; Almeida, A; Giagounidis, A; Fu, T; Sanna, A; Hoenekopp, A; Beach, CL; Skikne, B; Fenaux, P;
PUBLICAÇÃO: 2015, FONTE: 45th Congress of the Italian-Society-of-Hematology in HAEMATOLOGICA, VOLUME: 100
AUTORES: Santini, V; Shiansong S S Li; Swern, AS; Almeida, A; Giagounidis, A; Fu, T; Sanna, A; Hoenekopp, A; Beach, CL; Skikne, B; Fenaux, P;
PUBLICAÇÃO: 2015, FONTE: 45th Congress of the Italian-Society-of-Hematology in HAEMATOLOGICA, VOLUME: 100
INDEXADO EM: 
WOS
WOS NO MEU: 
ORCID
ORCID63
TÃTULO: STUDY PHASE 3 OF LENALIDOMIDE (LEN) IN PATIENTS (PTES) WITH MYELODYSPLASTIC SYNDROME (SMD) WITHOUT DEL(5Q) OF LOW RISK AND WITH TRANSFUSIONAL DEPENDENCE (DT), REFRACTORIES OR NON RESPONSIVE TO STIMULATING AGENTS OF ERYTHROPOIESIS Full Text
AUTORES: Del Canizo, MC; Almeida, A; Giagounidis, A; Fenaux, P; Santini, V; Ozawa, K;
PUBLICAÇÃO: 2015, FONTE: 57th National Congress of the Spanish-Society-of-Hematology-and-Hemotherapy in HAEMATOLOGICA, VOLUME: 100
AUTORES: Del Canizo, MC; Almeida, A; Giagounidis, A; Fenaux, P; Santini, V; Ozawa, K;
PUBLICAÇÃO: 2015, FONTE: 57th National Congress of the Spanish-Society-of-Hematology-and-Hemotherapy in HAEMATOLOGICA, VOLUME: 100
INDEXADO EM: WOS
WOS NO MEU: ORCID
ORCID64
TÃTULO: Safety of Lenalidomide (LEN) 10mg in Non-Del(5q) Versus Del(5q) in the Treatment of Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (MDS): Pooled Analysis of Treatment-Emergent Adverse Events (TEAEs)
AUTORES: Almeida, A; Santini, V; Cropper, S; Jonasova, A; Vey, N; Giagounidis, A; Hellstrom Lindberg, E; Mufti, GJ; Sanz, G; Skikne, B; Hoenekopp, A; Seguy, F; Zhong, JH; Fenaux, P;
PUBLICAÇÃO: 2015, FONTE: 57th Annual Meeting of the American-Society-of-Hematology in BLOOD, VOLUME: 126, NÚMERO: 23
AUTORES: Almeida, A; Santini, V; Cropper, S; Jonasova, A; Vey, N; Giagounidis, A; Hellstrom Lindberg, E; Mufti, GJ; Sanz, G; Skikne, B; Hoenekopp, A; Seguy, F; Zhong, JH; Fenaux, P;
PUBLICAÇÃO: 2015, FONTE: 57th Annual Meeting of the American-Society-of-Hematology in BLOOD, VOLUME: 126, NÚMERO: 23
65
TÃTULO: Clinical Benefit of Eculizumab in Patients with No Transfusion History in the International Paroxysmal Nocturnal Hemoglobinuria Registry
AUTORES: Antonio Medina Almeida; Camille L Bedrosian; Alexander Cole; Petra Muus; Hubert Schrezenmeier; Jeff Szer; Alvaro Urbano Ispizua; Wendell F Rosse;
PUBLICAÇÃO: 2015, FONTE: 57th Annual Meeting of the American-Society-of-Hematology in BLOOD, VOLUME: 126, NÚMERO: 23
AUTORES: Antonio Medina Almeida; Camille L Bedrosian; Alexander Cole; Petra Muus; Hubert Schrezenmeier; Jeff Szer; Alvaro Urbano Ispizua; Wendell F Rosse;
PUBLICAÇÃO: 2015, FONTE: 57th Annual Meeting of the American-Society-of-Hematology in BLOOD, VOLUME: 126, NÚMERO: 23
INDEXADO EM: WOS
WOS66
TÃTULO: Different Clinical Characteristics of Paroxysmal Nocturnal Hemoglobinuria in Pediatric and Adult Patients
AUTORES: Alvaro Urbano Ispizua; Petra Muus; Hubert Schrezenmeier; Antonio Medina Almeida; Amanda Vilson; Russell E Ware;
PUBLICAÇÃO: 2015, FONTE: 57th Annual Meeting of the American-Society-of-Hematology in BLOOD, VOLUME: 126, NÚMERO: 23
AUTORES: Alvaro Urbano Ispizua; Petra Muus; Hubert Schrezenmeier; Antonio Medina Almeida; Amanda Vilson; Russell E Ware;
PUBLICAÇÃO: 2015, FONTE: 57th Annual Meeting of the American-Society-of-Hematology in BLOOD, VOLUME: 126, NÚMERO: 23
INDEXADO EM: WOS
WOS67
TÃTULO: REAL-WORLD EVIDENCE OF IRON CHELATION THERAPY IN TRANSFUSION DEPENDENT MDS PATIENTS: A PORTUGUESE HOSPITAL REGISTRY
AUTORES: Rodrigues, S; Almeida, A; Viriato, D; Antunes, M ;
PUBLICAÇÃO: 2015, FONTE: 18th ISPOR Annual European Congress in VALUE IN HEALTH, VOLUME: 18, NÚMERO: 7
AUTORES: Rodrigues, S; Almeida, A; Viriato, D; Antunes, M ;
PUBLICAÇÃO: 2015, FONTE: 18th ISPOR Annual European Congress in VALUE IN HEALTH, VOLUME: 18, NÚMERO: 7
68
TÃTULO: THE EFFECT OF LENALIDOMIDE ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH MDS: RESULTS FROM THE MDS-005 TRIAL Full Text
AUTORES: Santini, V; Almeida, A; Giagounidis, A; Bartiromo, C; Hoenekopp, A; Guo, S; Beach, CL; Altincatal, A; Wu, C; Skikne, B; Zhong, J; Hu, XH; Fenaux, P;
PUBLICAÇÃO: 2015, FONTE: 13th International Symposium on Myelodysplastic Syndromes (MDS) in LEUKEMIA RESEARCH, VOLUME: 39
AUTORES: Santini, V; Almeida, A; Giagounidis, A; Bartiromo, C; Hoenekopp, A; Guo, S; Beach, CL; Altincatal, A; Wu, C; Skikne, B; Zhong, J; Hu, XH; Fenaux, P;
PUBLICAÇÃO: 2015, FONTE: 13th International Symposium on Myelodysplastic Syndromes (MDS) in LEUKEMIA RESEARCH, VOLUME: 39
INDEXADO EM: WOS
WOS69
TÃTULO: A PHASE 3 STUDY OF LENALIDOMIDE VERSUS PLACEBO IN RBC TRANSFUSION-DEPENDENT (TD) PATIENTS WITH LOWER-RISK MDS WITHOUT DEL(5Q) UNRESPONSIVE OR REFRACTORY TO ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) Full Text
AUTORES: Santini, V; Almeida, A; Giagounidis, A; Groepper, S; Jonasova, A; Vey, N; Mufti, GJ; Buckstein, R; Mittelman, M; Platzbecker, U; Shpilberg, O; Ram, R; del Canizo, C; Gattermann, N; Ozawa, K; Risueno, A; MacBeth, KJ; Zhong, J; Seguy, F; Hoenekopp, A; ...Mais
PUBLICAÇÃO: 2015, FONTE: 13th International Symposium on Myelodysplastic Syndromes (MDS) in LEUKEMIA RESEARCH, VOLUME: 39
AUTORES: Santini, V; Almeida, A; Giagounidis, A; Groepper, S; Jonasova, A; Vey, N; Mufti, GJ; Buckstein, R; Mittelman, M; Platzbecker, U; Shpilberg, O; Ram, R; del Canizo, C; Gattermann, N; Ozawa, K; Risueno, A; MacBeth, KJ; Zhong, J; Seguy, F; Hoenekopp, A; ...Mais
PUBLICAÇÃO: 2015, FONTE: 13th International Symposium on Myelodysplastic Syndromes (MDS) in LEUKEMIA RESEARCH, VOLUME: 39
INDEXADO EM: WOS
WOS NO MEU: ORCID
ORCID70
TÃTULO: EFFICACY OF AZACITIDINE IN MDS, CMML AND AML WITH PROLIFERATIVE FEATURES Full Text
AUTORES: Almeida, AM; Pierdomenico, F;
PUBLICAÇÃO: 2015, FONTE: 13th International Symposium on Myelodysplastic Syndromes (MDS) in LEUKEMIA RESEARCH, VOLUME: 39
AUTORES: Almeida, AM; Pierdomenico, F;
PUBLICAÇÃO: 2015, FONTE: 13th International Symposium on Myelodysplastic Syndromes (MDS) in LEUKEMIA RESEARCH, VOLUME: 39
INDEXADO EM: WOS
WOS